TapImmune Inc. Signs License Agreement With Crucell N.V.

November 5, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

BELLEVUE, Wash., Nov. 5, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed a license agreement with Crucell N.V.

Twitter
LinkedIn
Facebook
Email
Print

Alliances